Grifols

Caring for people also means caring for the environment. 🌱 We proudly operate two production facilities with Green Globe certifications as well as three LEED-certified buildings in Spain, the U.S. and Canada. In Montréal, we are constructing Canada’s first and only large-scale plasma fractionation complex. This project is being carried out in accordance with environmental standards to achieve a new LEED certification. 🎯 Our goal is to build as sustainably as possible while minimizing environmental impact during the construction phase. How many kilograms of material do you think can be recovered in the construction of 22865 m² building? Discover 👇 #LEED #Greenbuilding #PositiveImpact

On February 28th, Rare Disease Day is celebrated across the world. It is an important coordinated movement for raising awareness and generating change for the 300 million people worldwide living with rare diseases, their families and caregivers. This month, we want to actively empower social participation by raising awareness. Do you need a reason to embrace #RareDiseaseDay? Here are our 5 reasons 👇 #GiveAHand #ShareYourColours

We believe that great talent deserves great support. That’s why mentoring is a key pillar of our high-potential development programs GROW and TALENT Programs.  Through these initiatives, employees gain valuable insights, refine their skills, and strengthen their leadership capabilities with the guidance of experienced professionals.  For many participants, mentoring has been a game-changer: 🔹 “The mentoring program has been a truly transformative experience”, Sònia Busquets Oliu. 🔹 "It provides a fresh perspective with valuable advice and recommendations”, Joan Raventós Nosàs 🔹 "This incredible opportunity, with my mentor, Kate Larsen, marks the beginning of a new adventure. Ready to grow and thrive within the #GrifolsTeam", Christopher Vogelheim More than just career advice, mentoring at Grifols fosters a culture of continuous learning and collaboration.  #Mentoring #CareerGrowth #FutureLeaders  

Our Chief Corporate Affairs, Legal & Data Protection Officer interviewed by Plasma Protein Therapeutics Association (PPTA)’s president, Anita Brikman. David Bell reflects on why we set the highest quality standards for ourselves. #WeAreHealthcare

We are happy to announce the completion of recruitment for the second cohort in our study on the safety and tolerability of two doses of subcutaneous alpha-1 protease inhibitor (15%) for treating alpha-1 antitrypsin deficiency (AAT). This study compares the subcutaneous route of administration option with the intravenous one. If approved, this would be the first subcutaneous treatment for alpha-1 antitrypsin deficiency. It would provide patients with added convenience and flexibility to administer their medication from home. We remain committed to the alpha-1 patient community and to reaching those yet to be diagnosed. Learn more 👉 http://spr.ly/6041IaPlD #WeAreHealthcare #Alpha1Awareness #geneticcopd

In 1995, we became the first Spanish company to obtain FDA approval for a biological product. Our Parets del Vallès facility received its Establishment License, and the albumin produced there was granted a Product License—marking a key milestone in our history. This recognition not only allowed us to enter the U.S. market but also reinforced our commitment to the highest quality standards. Decades of dedication, continuous improvement, and collaboration with international partners paved the way for this achievement. Three decades later, we continue to innovate and uphold our mission of ensuring the highest levels of quality and safety in everything we do. More info 👉 http://spr.ly/6040ISj4n #Since1909 #FDA

🌱 S&P Global has once again recognized our commitment to sustainability by including us in the Sustainability Yearbook 2025. Being in the top 1% of our industry reaffirms our leadership in responsible business practices and our long-term sustainability strategy. We will continue driving innovation and contributing to a more sustainable future for all. #PositiveImpact #SustainabilityIndice

Representation matters. Having role models to look up to builds opportunities. At Grifols, we are beyond proud to help foster professional development and share in the achievements of women in fields such as engineering, IT security, biotechnology, microbiology, computational biology, lab technology and many more. That’s why we want to celebrate the 10th Anniversary of the International Day of Women and Girls in Science by shining a spotlight on some of the successful women who are developing their STEM careers within our company. #WeAreGrifols #womeninscience #womeninstem

Thank you. Yes, YOU! 🎉 We’ve reached a major milestone: 250,000 followers here on LinkedIn This achievement is a testament to the strength of Grifols’ global community and our ongoing commitment to connecting with professionals in the biopharmaceutical industry. 🙏 Your engagement helps us connect, grow and continue to inspire others in the healthcare space. Here's to continuing the conversation and reaching new heights together! Thank you for your support! #WeAreGrifols

We are proud to announce that Grifols has been awarded the national plasma fractionation service contract for the supply of plasma-derived medicines in Spain. Valued at €281 million, this contract includes the supply of immunoglobulin, albumin, factor VIII, alpha-1-antitrypsin, factor IX and antithrombin III. This success not only reinforces our position in the market but also underlines our commitment to quality, safety, and innovation in the field of plasma-derived medicines. #WeAreHealthcare